Welcome Guest | Register / Login

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

1. Table of Contents
1.1. List of Tables 5
1.2. List of Figures 7
2. Deal Values in Pharmaceutical and Healthcare Industry Increased in March2020 9
2.1. Pharmaceuticals & Healthcare, Deals Summary, March 2020 9
3. Pharmaceuticals & Healthcare, Global, Deal Summary, 13
3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2020 13
3.2. Pharmaceuticals & Healthcare, Global, Major Deals, March 2020 14
3.2.1. Thermo Fisher Scientific to Acquire Qiagen 15
3.2.2. Gilead Sciences Acquires Forty Seven 15
3.2.3. Silence Therapeutics Enters into Collaboration with Astrazeneca 16
3.2.4. CytomX Therapeutics Enters into Agreement with Astellas Pharma 16
3.2.5. Pfizer Raises USD1.25 Billion in Public Offering of 2.625% Notes Due 2030 17
3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2020 18
3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2020 19
4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2020 44
6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 59
7. Deal Summary by Geography 77
8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors 88
9. Further Information 92
9.1. Methodology 92
9.2. About GlobalData 93
9.3. Contact Us 93
9.4. Disclosure information 93
9.5. Disclaimer 93

1.1. List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 14
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2020 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2020 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2020 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019- March 2020 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2020 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 25
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 27
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2020 27
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2019- March 2020 28
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2020 30
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2019- March 2020 31
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2019- March 2020 32
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2019- March 2020 33
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 34
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 35
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2020 36
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 38
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019- March 2020 41
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2019- March 2020 43
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 45
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 47
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 49
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2020 51
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, October 2019- March 2020 54
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2020 56
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2020 56
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2020 57
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2020 58
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 60
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 63
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 66
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 69
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 72
Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 74
Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 76
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 78
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 81
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 83
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 86
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2019- March 2020 89
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2019- March 2020 91

1.2. List of Figures
sFigure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, March 2020 9
Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, October 2019 - March 2020 10
Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, March 2020 11
Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, March 2020 12
Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2019- March 2020 13
Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2020 18
Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2020 19
Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2019- March 2020 20
Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019- March 2020 22
Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2019- March 2020 23
Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 25
Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2019- March 2020 26
Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019- March 2020 28
Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2020 29
Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2020 30
Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2019- March 2020 31
Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2019- March 2020 33
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 34
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 35
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 37
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019- March 2020 39
Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019- March 2020 40
Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2019- March 2020 42
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2019- March 2020 44
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 46
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 48
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 50
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2019- March 2020 52
Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2019- March 2020 53
Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2020 55
Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2019- March 2020 59
Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2019- March 2020 62
Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2019- March 2020 65
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2019- March 2020 68
Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2019- March 2020 71
Figure 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 73
Figure 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 75
Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2019- March 2020 77
Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2019- March 2020 80
Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2019- March 2020 82
Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2019- March 2020 85
Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2019- March 2020 88
Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2019- March 2020 90
Single User License: Report will be emailed in PDF format and can be accessed by a specific user. This License type allows the report to be Printed.
Site License: Report will be emailed in PDF and  allows only employees within the same geographical location within the organization to access it. This License type allows the report to be Printed.
Global Site License: Report will be emailed in PDF format and allows all employees within the organization to access it.  This License type allows the report to be Printed.
Why http://www.marketreportsonline.com/
Published By :GlobalData
Price
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy